FORMULATION AND EVALUATION OF SUBLINGUAL TABLETS OF POORLY AQUEOUS-SOLUBLE DRUG TICAGRELOR USING SUPERDISINTEGRANTS

Ticagrelor is an oral antiplatelet drug that is used to decrease the risk of myocardial infarction and stroke in patients with acute coronary syndromes. Sublingual tablets, which disintegrate in the oral cavity beneath the tongue in less than a minute, are solid dosage forms that have the benefit of avoiding first-pass metabolism. The need for sublingual has increased over the past ten years, particularly among the elderly and kids who have swallowing issues. To achieve rapid disintegration in gastric pH and quick action as an oral antiplatelet agent, the current study's goal was to create sublingual tablets of Ticagrelor using various concentrations of Crosscarmellose Sodium, Sodium starch glycolate, and Cross povidone as superdisintegrants. There are twelve different sublingual tablet formulations were created using wet granulation technology. There is no interaction between the medications and the numerous excipients employed in the formulation, according to FTIR technology studies on the compatibility of drugs and excipients. When compared to the pharmacopeia, the outcomes of the various precompression and postcompression characterizations of tablets were satisfactory. Using a USP II paddle-type dissolution equipment, in vitro release experiments for several formulations were carried out. Formulation TSF₁₂, which contains 2% Crosscarmellose Sodium and 2% Cross povidone, demonstrated complete drug release in less than 30 minutes (>99%), establishing itself as an optimized formulation. Using both superdisintegrants in tandem also demonstrated an improved drug release profile. The zero-order kinetic model was the best formulation. Accelerated stability studies for improved formulation were done to confirm the stability of dosage forms.

Keywords: Ticagrelor, Sublingual tablet, Croscarmellose Sodium, Sodium starch glycolate, Cross povidone, antiplatelet drug.